Compare ARMOUR Residential REIT, Inc. (ARR) vs BioNano Genomics Inc (BNGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARMOUR Residential REIT, Inc. vs BioNano Genomics Inc — how do they compare? ARMOUR Residential REIT, Inc. trades at $16.69 (market cap $2.07B), while BioNano Genomics Inc trades at $1.17 (market cap $13.66M). The key difference: ARMOUR Residential REIT, Inc. is far larger — about 151.5× BioNano Genomics Inc's market cap, and ARMOUR Residential REIT, Inc. pays a 17.28% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| ARR | BNGO | |
|---|---|---|
Market Cap | $2.07B | $13.66M |
Sector | Financials | Health |
52-Week High | $19.12 | $4.92 |
52-Week Low | $14.05 | $1.06 |
Dividend Yield | 17.28% | — |
Enterprise Value | — | $16.26M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARMOUR Residential REIT (ARR) trades at $16.54, down 0.84% on the day, amid a bearish technical signal. The stock shows a low P/E of 3.78 and trades below book value (P/B 0.91), suggesting potential undervaluation. Recent earnings were mixed, with a Q2 2026 beat but a Q4 2025 miss. The company maintains a high net income margin of 97.43% and consistent dividend payments, with the latest being $0.24 per share. Cash flow from operations improved to $319 million in 2026, though investing outflows remain high.
ARR presents a value opportunity with strong profitability and dividends, but faces risks from volatile earnings, high investing cash outflows, and a bearish technical outlook. Analyst sentiment is mixed, with 60% hold ratings. The stock's appeal hinges on sustained dividend payments and earnings stability amid interest rate sensitivity.
BNGO trades at $1.16 with a bullish technical signal supported by moving averages. The company shows improving financial trends with narrowing losses and consistent earnings beats, though it remains unprofitable with negative margins. Recent news highlights operational progress including debt retirement and scientific publications. Valuation ratios appear attractive with P/S of 0.31 and P/B of 0.36.
The outlook remains speculative given persistent losses, but improving cash flow trends and analyst optimism provide catalysts. Key risks include ongoing negative profitability and competitive pressures in genomics. With 57% analyst buy ratings and bullish technical momentum, the stock offers high-risk growth potential for investors comfortable with biotech volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARMOUR Residential REIT, Inc.
ARMOUR Residential REIT Inc is a real estate investment trust that invests in residential mortgage-backed securities or RMBS. These are issued or guaranteed by U.S.-government-sponsored enterprises, such as Fannie Mae, Freddie Mac, or Ginnie Mae. The company's investment portfolio is composed of mortgage-backed securities, adjustable-rate mortgage securities, and multifamily mortgage-backed securities. In terms of total fair value, most Armour's investments are long-term, fixed-rate agency RMBS. Multifamily RMBS also represents a substantial amount. Fannie Mae guarantees most of the company's holdings. Armour derives substantially all its revenue as interest income from its investments.
Read more on ARR →About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →
